Here’s what you should know:
1. The company reported a 9 percent growth in year-over-year revenue.
2. Allergan posted net generally accepted accounting principle operating income of $1.9 billion, a 1.6 percent year-over-year increase.
3. Allergan’s Botox drove second quarter sales.
4. Concerning its gastrointestinal sector, Allergan’s Linzess led the quartet of products with $167.8 million in revenues. Asacol/Delzicol revenues decreased 61.9 percent year-over-year to $45.6 million.
5. Concerning rest-of-year outlooks, Allergan expects net revenues between $15.85 billion and $16.05 billion.
More articles on gastroenterology:
Gastro Health acquires ASC & more: 3 GI practices in the news
Gastro Health acquires Gastrointestinal Center of Hialeah — 4 insights
Northwell Health Physician Partners opens multispecialty practice— 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
